Research Paper Volume 14, Issue 6 pp 2868—2879
TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
Figure 1. Prevalence of TP53/BRAF mutations in pan-cancer.
Figure 1. Prevalence of TP53/BRAF mutations in pan-cancer.